TELA Bio, Inc. (TELA)
NASDAQ: TELA · Real-Time Price · USD
0.8140
+0.0330 (4.23%)
Sep 4, 2026, 10:47 AM EDT - Market open
TELA Bio Revenue
TELA Bio had revenue of $19.29M in the quarter ending June 30, 2026, a decrease of -4.49%. This brings the company's revenue in the last twelve months to $79.91M, up 6.09% year-over-year. In the year 2025, TELA Bio had annual revenue of $80.28M with 15.84% growth.
Revenue (ttm)
$79.91M
Revenue Growth
+6.09%
P/S Ratio
0.47
Revenue / Employee
$366,550
Employees
218
Market Cap
36.54M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 80.28M | 10.98M | 15.84% |
| Dec 31, 2024 | 69.30M | 10.85M | 18.56% |
| Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
| Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
| Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
| Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
| Dec 31, 2019 | 15.45M | 7.17M | 86.68% |
| Dec 31, 2018 | 8.27M | 4.03M | 94.91% |
| Dec 31, 2017 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 401.95M |
| Nortech Systems | 124.65M |
| SANUWAVE Health | 44.02M |
| QT Imaging Holdings | 26.43M |
| Baird Medical Investment Holdings | 24.49M |
| Nano-X Imaging | 14.52M |
| Elutia | 12.14M |
| InspireMD | 10.84M |
TELA News
- 4 days ago - Tela Bio COO, CFO Roberto Cuca steps down - TheFly
- 4 days ago - TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative - GlobeNewsWire
- 24 days ago - Tela Bio reports Q2 EPS (20c), consensus (18c) - TheFly
- 24 days ago - Tela Bio withdraws FY26 guidance - TheFly
- 24 days ago - TELA Bio Earnings Call Transcript: Q2 2026 - Transcripts
- 24 days ago - TELA Bio Earnings release: Q2 2026 - Filings
- 24 days ago - TELA Bio Quarterly report: Q2 2026 - Filings
- 4 weeks ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire